Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H1 2017

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H1 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H1 2017, provides an overview of the Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline landscape.

MRSA infections that are acquired by persons who have not been recently (within the past year) hospitalized or had a medical procedure (such as dialysis, surgery, catheters) are known as community-acquired MRSA (CA-MRSA) infections. Risk factors are hemodialysis, weakened immune system, admission to hospitals and wounds. Symptoms include skin rashes, fatigue, chest pain, fever and swelling. MRSA can be managed by the use of antibiotics and by maintaining hygienic conditions.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 14, 10, 70, 31 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 23 and 22 molecules, respectively.

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
Table of Contents 2
Introduction 6
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Overview 7
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Therapeutics Development 8
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Therapeutics Assessment 32
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Companies Involved in Therapeutics Development 43
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Drug Profiles 83
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects 336
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Discontinued Products 343
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Product Development Milestones 344
Appendix 356

List Of Tables

Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Products under Development by Companies, H1 2017 (Contd..6), H1 2017
Products under Development by Universities/Institutes, H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AbbVie Inc, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Absynth Biologics Ltd, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Actelion Ltd, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Adenium Biotech ApS, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Alchemia Ltd, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Allergan Plc, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AmpliPhi Biosciences Corp, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Antibiotx ApS, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Aphios Corp, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Aridis Pharmaceuticals LLC, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AstraZeneca Plc, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Atriva Therapeutics GmbH, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Bavarian Nordic A/S, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Bharat Biotech International Ltd, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by C3J Therapeutics Inc, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Cellceutix Corp, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Cempra Inc, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Citius Pharmaceuticals Inc, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Common Pharma Inc, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by ContraFect Corp, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Crestone Inc, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Critical Outcome Technologies Inc, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by CrystalGenomics Inc, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by CytaCoat AB, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Debiopharm International SA, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Dermala Inc, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by DesignMedix Inc, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Destiny Pharma Ltd, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Emergent BioSolutions Inc, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Ensol Biosciences Inc, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Galapagos NV, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by GangaGen Inc, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Helix BioMedix Inc, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Hsiri Therapeutics LLC, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Ildong Pharmaceutical Co Ltd, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Immupharma Plc, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by iNtRON Biotechnology Inc, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by ioGenetics Inc, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Lead Discovery Center GmbH, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by LegoChem Biosciences Inc, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Lipocure Ltd, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Madam Therapeutics BV, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Melinta Therapeutics Inc, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Merck & Co Inc, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Microbiotix Inc, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by MicuRx Pharmaceuticals Inc, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by MorphoSys AG, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Motif Bio Plc, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Nabriva Therapeutics AG, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Nemus Bioscience Inc, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Novabiotics Ltd, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by NovaDigm Therapeutics Inc, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Novalex Therapeutics Inc, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by NovoBiotic Pharmaceuticals LLC, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Oragenics Inc, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Ovensa Inc, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Pfizer Inc, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Phico Therapeutics Ltd, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Prommune Inc, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Recce Ltd, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Savara Inc, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Sealife PHARMA GMBH, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Soligenix Inc, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Sorrento Therapeutics Inc, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Taejoon Pharm Co Ltd, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by TAXIS Pharmaceuticals Inc, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Telephus Medical LLC, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Tetraphase Pharmaceuticals Inc, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Theravance Biopharma Inc, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Trellis Bioscience Inc, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Valevia UK Ltd, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by VLP Biotech Inc, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Wockhardt Ltd, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by XBiotech Inc, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Yungjin Pharm Co Ltd, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects, H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects, H1 2017 (Contd..1), H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects, H1 2017 (Contd..2), H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects, H1 2017 (Contd..3), H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects, H1 2017 (Contd..4), H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects, H1 2017 (Contd..5), H1 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Discontinued Products, H1 2017

List Of Figures

Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Top 10 Routes of Administration, H1 2017
Number of Products by Stage and Top 10 Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available